A multicenter, open-label, phase I/II study of IBI130, a TROP2-targeting antibody–drug conjugate, as monotherapy in patients with recurrent or metastatic cervical cancer

Gynecologic Oncology 2026

View at publisher

Authors: Qin Xu, Xingyun Xie, Yuting Shi, Yaxin Kang, Huaqin Lin, Qingzhen Zhan

DOI: 10.1016/j.ygyno.2026.01.781

Cited by: 1

Fields of Study & Subjects

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Protease and Inhibitor Mechanisms